LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

Search

Codexis Inc

Atvērts

SektorsVeselības aprūpe

2.48 4.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.31

Max

2.48

Galvenie mērījumi

By Trading Economics

Ienākumi

7.4M

-13M

Pārdošana

7.8M

15M

EPS

-0.16

Peļņas marža

-86.587

Darbinieki

188

EBITDA

7.6M

-13M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+154.22% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 30. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-12M

220M

Iepriekšējā atvēršanas cena

-2.16

Iepriekšējā slēgšanas cena

2.48

Ziņu noskaņojums

By Acuity

50%

50%

167 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Codexis Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. sept. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025. g. 17. sept. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025. g. 17. sept. 21:59 UTC

Peļņas

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025. g. 17. sept. 23:44 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 17. sept. 23:39 UTC

Tirgus saruna

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025. g. 17. sept. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025. g. 17. sept. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025. g. 17. sept. 21:00 UTC

Peļņas

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025. g. 17. sept. 19:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 17. sept. 18:43 UTC

Tirgus saruna

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025. g. 17. sept. 18:38 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025. g. 17. sept. 18:20 UTC

Tirgus saruna

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025. g. 17. sept. 18:14 UTC

Tirgus saruna

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025. g. 17. sept. 17:59 UTC

Tirgus saruna

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025. g. 17. sept. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025. g. 17. sept. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025. g. 17. sept. 16:51 UTC

Peļņas

Correct: Exor 1H Net Loss -EUR624M

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025. g. 17. sept. 16:25 UTC

Peļņas

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025. g. 17. sept. 16:23 UTC

Peļņas

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Salīdzinājums

Cenas izmaiņa

Codexis Inc Prognoze

Cenas mērķis

By TipRanks

154.22% augšup

Prognoze 12 mēnešiem

Vidējais 6.33 USD  154.22%

Augstākais 11 USD

Zemākais 3 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Codexis Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

3

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.25 / 2.53Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

167 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat